Mersana Therapeutics price target lowered to $10 from $15 at Citi

Citi analyst Ashiq Mubarack lowered the firm’s price target on Mersana Therapeutics to $10 from $15 and keeps a Buy rating on the shares. The company’s announcement of a partial clinical hold “comes as a complete surprise,” the analyst tells investors in a research note. Though the UpRi development risk is now increased, it remains too soon to write off the program, says the firm.